Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing the Company's Expanded ADC Pipeline

Core Insights - Akari Therapeutics is expanding its antibody drug conjugate (ADC) pipeline and intellectual property strategy, as discussed by CEO Abizer Gaslightwala in a recent virtual investor interview [2][4] - The company is advancing its lead ADC program, AKTX-101, towards IND and CTA submissions, aiming for first-in-human studies by late 2026 or early 2027 [4][6] ADC Pipeline Expansion - Akari has introduced AKTX-102, its second ADC candidate targeting CEACAM5-expressing solid tumors, highlighting the scalability of its PH1-powered ADC platform [3][4] - The company’s differentiated approach to CEACAM5 involves a novel antibody construct combined with the PH1 spliceosome-modulating payload [4] Intellectual Property Strategy - The recent patent filing underscores the strategic importance of Akari's growing patent estate, which supports long-term value creation and potential partnering opportunities [4] - The company aims to leverage its innovative ADC discovery platform to generate and optimize ADC candidates for various antigen targets [6] Lead Program Details - AKTX-101 targets the Trop2 receptor on cancer cells, utilizing a proprietary linker to deliver the PH1 payload directly into tumors with minimal off-target effects [6] - Preclinical studies indicate that AKTX-101 has significant activity and prolonged survival compared to traditional ADCs, with potential synergy with checkpoint inhibitors [6]